The potential federal rescheduling of cannabis, which could lead to significant 280E tax relief for U.S. operators, may see its financial benefits partially or entirely offset by existing tariffs. This analysis, presented by Justin Leiby, a professor of accountancy at the University of Illinois and faculty at the Cannabis Research Institute, highlights how the interplay of tax changes and import duties could reshape the competitive landscape for cannabis businesses, as detailed in a report by Marijuana Moment.

As previously reported by Hemp Gazette concerning the federal rescheduling of medical cannabis, the reclassification of cannabis from Schedule I to Schedule III under the Controlled Substances Act would remove the Section 280E tax penalty. This provision currently disallows ordinary business deductions for companies dealing in Schedule I or II substances, imposing a substantial financial burden on cannabis operators.

The Financial Burden of 280E

Section 280E has been a significant financial constraint for cannabis businesses. According to an annual survey of cannabis operators conducted for the Illinois Cannabis Regulation Oversight Office, operators estimated that 44 percent of their 2024 operating expenses were nondeductible under 280E. Leiby’s analysis indicates that, assuming a 21 percent corporate tax rate, this translates to a US$92 penalty for every US$1,000 spent, or approximately three cents per dollar of revenue when considering average disallowance and SG&A percentages.

The impact of 280E has not been uniform across the industry:

• Smaller operators reported higher disallowances, averaging 45 percent of operating expenses, compared to 37 percent for larger companies.
• Companies relying entirely on dispensary operations faced greater disallowances, at 50 percent of operating expenses, versus 43 percent for those with diversified operations.

The elimination of this penalty, therefore, represents a considerable financial opportunity, particularly given the typically small profit margins within the cannabis sector.

Tariffs and Rising Input Costs

While 280E tax relief offers a clear benefit, the concurrent impact of tariffs on imported goods could diminish these gains. Tariffs primarily affect the direct costs of acquiring and producing products, known as “costs of goods sold,” which constitute a larger portion of overall operating costs than the indirect selling, general, and administrative expenses (SG&A) primarily impacted by 280E.

Leiby’s research, combining survey responses and public financial filings, illustrates the scale of this issue:

• One in six cannabis operators reported input cost increases of 20 percent or more.
• Over half of operators noted increases of 5 percent or more in input costs.

These increases are attributed to tariffs on items such as packaging, vape hardware, and construction materials. The analysis suggests that even a modest 5 percent increase in input costs could diminish most of the financial benefit from 280E penalty relief, while an 18 percent increase erases all profits altogether.

Differential Impacts and Competitive Landscape

Similar to 280E, the burden of tariffs is not evenly distributed. Cultivation and infusion operations, which often rely heavily on imported packaging, build-out materials, and high-tech hardware, are more significantly affected. For instance, 17 percent of cultivation and infusion companies reported input cost spikes exceeding 20 percent, whereas no dispensary-only companies reported such an impact.

This differential exposure suggests that dispensary-heavy companies, which face larger tax distortions from 280E and report smaller impacts from tariffs, may emerge as the primary beneficiaries of the anticipated 280E tax relief. However, the full realization of these benefits may be delayed, as operators have made long-term strategic decisions based on the previous 280E constraints and cannot unwind these choices instantly. The Illinois survey indicated that over half of operators had cut discretionary investments in product development, research, and sustainable technologies, and adopted leaner staffing models or modified facility layouts due to tax considerations. The ability of operators to adapt to this evolving regulatory and economic landscape will determine their capacity to capture the gains from rescheduling.

---

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.